# Fully Automated Sponsor: Physical AI Oncology Clinical Trials

Complete LaTeX source for the autonomous AI-native sponsor operating system paper (v3.2.0).
This paper specifies a twelve-agent, four-layer architecture that replaces traditional
human-staffed pharmaceutical sponsor functions for Physical AI oncology clinical trials.

**Note:** The final version with automated code generations, execution results, and updated
appendices is in `sponsor/final_paper/` (v3.3.0). This directory contains the original
v3.2.0 paper with the code generation instructions in Appendices E and F.

## File Structure

```
sponsor/paper/
|-- main.tex                         # Main document entry point (18 sections + appendices)
|-- sponsor_paper.sty                # Style file (adapted from arxiv.sty, CC BY 4.0)
|-- references.bib                   # Bibliography (48+ entries with DOIs and URLs)
|-- orcid_icon.png                   # ORCID icon for author attribution
|-- README.md                        # This file
|-- sections/
|   |-- introduction.tex             # Section 1: Introduction and paper roadmap
|   |-- governance.tex               # Section 2: Board/portfolio/asset agents, decision gates
|   |-- trial_design.tex             # Section 3: Protocol design, biomarkers, biostatistics
|   |-- clinical_operations.tex      # Section 4: Study orchestrator, ClinOps, enrollment
|   |-- safety_pharmacovigilance.tex # Section 5: Safety agent, E2B(R3), robotic safety
|   |-- regulatory_affairs.tex       # Section 6: IND/CTA automation, accelerated pathways
|   |-- quality_compliance.tex       # Section 7: Quality agent, RBQM, electronic systems
|   |-- supply_chain.tex             # Section 8: Supply agent, CMC, robotic pharmacy
|   |-- data_management.tex          # Section 9: Data pipeline, CDISC, federated data
|   |-- robotic_execution.tex        # Section 10: Robot gateway, capability registry
|   |-- site_interface.tex           # Section 11: Site gateway, FHIR/DICOM/MCP integration
|   |-- trust_layer.tex              # Section 12: Identity, audit, provenance, policy engine
|   |-- vendor_management.tex        # Section 13: Vendor mesh, CRO accountability matrix
|   |-- writing_disclosure.tex       # Section 14: Document generation, disclosure, archiving
|   |-- financial_analysis.tex       # Section 15: Cost modeling, ROI, timeline compression
|   |-- implementation_strategy.tex  # Section 16: 3-phase national deployment strategy
|   |-- discussion.tex               # Section 17: Paradigm shift, challenges, limitations
|   |-- conclusion.tex               # Section 18: Summary of contributions and future work
|   |-- appendices.tex               # Appendices A-D: Agent registry, script directory,
|                                    #   source cross-reference, regulatory compliance mapping
```

## Architecture Overview

The autonomous sponsor comprises 12 functional agents organized into 4 layers:

1. **Governance Layer**: portfolio_agent, asset_lead_agent, board agent cluster
2. **Study Execution Layer**: clinical_accountability_agent, study_orchestrator,
   clinops_agent, safety_agent, regulatory_agent, quality_agent, supply_agent,
   data_biostats_agent
3. **Site/Robotics Layer**: site_gateway, robot_execution_gateway
4. **Trust Layer**: Identity, authorization, audit, provenance, policy enforcement

## LaTeX Compilation

```bash
cd sponsor/paper
pdflatex main.tex
bibtex main
pdflatex main.tex
pdflatex main.tex
```

## Key Statistics

- 18 main sections plus 4 appendices
- 30 tables across all sections
- 49 Python scripts specified across 14 functional areas
- 48+ bibliography entries with DOIs and URLs
- 12 autonomous agents mapped to traditional sponsor roles

## Source Documents

This paper synthesizes content from:
- sponsor/input_files/ (16 markdown files: 8 sponsor playbook + 7 organization + README)
- national-platform/new_paper/final_paper/ (21 section .tex files)
- new-trial/ (24-hour simulation with 168 patients across 10 robot categories)

## Citation

```bibtex
@misc{sponsor-paper,
  author = {Kawchak, Kevin},
  title = {Fully Automated Sponsor: Physical {AI} Oncology Clinical Trials},
  year = {2026},
  howpublished = {Zenodo},
  doi = {10.5281/zenodo.19396256},
  note = {DOI: 10.5281/zenodo.19396256.
    GitHub: https://github.com/kevinkawchak/physical-ai-oncology-trials/tree/main/sponsor.
    Zenodo: https://doi.org/10.5281/zenodo.19396256}
}
```

## Table Index

| Table | Title | Section |
|-------|-------|---------|
| 1 | Governance Agent Mapping | Section 2 |
| 2 | Decision Gate Framework | Section 2 |
| 3 | Trial Design Pattern Comparison | Section 3 |
| 4 | Estimand Framework Components | Section 3 |
| 5 | Study Startup Automation Workflow | Section 4 |
| 6 | Failure Mode Mitigation Matrix | Section 4 |
| 7 | Safety Reporting Timeline | Section 5 |
| 8 | Robotic Safety Event Classification | Section 5 |
| 9 | Global Regulatory Filing Matrix | Section 6 |
| 10 | Accelerated Pathway Comparison | Section 6 |
| 11 | QTL/KRI Framework | Section 7 |
| 12 | Electronic Systems Validation | Section 7 |
| 13 | IMP Supply Chain Automation | Section 8 |
| 14 | Robotic Pharmacy Operations | Section 8 |
| 15 | Data Supply Chain Pipeline | Section 9 |
| 16 | Federated Data Architecture | Section 9 |
| 17 | Robotic System Registry | Section 10 |
| 18 | Procedure Safety Gate Protocol | Section 10 |
| 19 | Site Systems Integration Matrix | Section 11 |
| 20 | Site Readiness Assessment | Section 11 |
| 21 | Trust Layer Architecture | Section 12 |
| 22 | Safety Gate Classification | Section 12 |
| 23 | Sponsor vs. CRO Accountability | Section 13 |
| 24 | Vendor SLA Framework | Section 13 |
| 25 | Document Generation Pipeline | Section 14 |
| 26 | Disclosure Timeline Requirements | Section 14 |
| 27 | Traditional vs. Autonomous Cost | Section 15 |
| 28 | Timeline Compression Analysis | Section 15 |
| 29 | Implementation Phase Timeline | Section 16 |
| 30 | Implementation Risk Matrix | Section 16 |

## License

This article is distributed under CC BY 4.0. The style file is adapted from arxiv.sty
(CC BY 4.0). This work is not endorsed or sponsored by CFR, ICH, or FDA.
